Kornimate/medical-research-clean huggingface dataset:
clinical outcomes after dry needling on cervical muscles, and quality of life, in patients with fibromyalgia syndrome.

Conditions: Fibromyalgia

Summary: objectives: the purpose of the current randomized clinical trial is to compare the effectiveness of dry needling versus myofascial release therapy on myofascial trigger points (mtrps) in cervical muscles, quality of life, fatigue, quality of sleep, anxiety and depression in patients with fibromyalgia syndrome (fms).

design: a single-blind randomized controlled trial will be conducted on patients with fms. methods: sixty-four subjects with fms will be randomly assigned to an experimental group receiving dry needling therapy, or to a control group for myofascial release therapy in the trigger points active or latent in the following pairs of muscles: occipital, splenius capitis, sternocleidomastoid, scalene, trapezius, supraspinatus, infraspinatus, and multifidus. myofascial trigger points, quality of life, impact of fibromyalgia symptoms, quality of sleep, intensity of pain, anxiety levels, state of depression, impact of fatigue will be recorded at baseline and after four weeks of treatment.

Eligibility criteria:
inclusion criteria: * fibromyalgia syndrome diagnosis. * aged from 18 to 60 years. * no regular physical activity. * limitation of usual activities due to pain on at least 1 day in the previous 30 days. * agreement to attend evening therapy sessions exclusion criteria: * receipt of any no pharmacologic therapies. * presence of cardiac, renal or hepatic insufficiency. * severe physical disability. * comorbid condition (eg, inflammatory disease). * infection fever. * hypotension. * skin alterations. * psychiatric illness. * previous history of surgery.

Keywords: quality of life fatigue anxiety physical therapy modalities pain
a study of dostarlimab in untreated dmmr/msi-h locally advanced rectal cancer

Conditions: Neoplasms, Rectal

Summary: the purpose of this study is to investigate dostarlimab monotherapy in participants with locally advanced mismatch-repair deficient (dmmr)/microsatellite instability-high (msi-h) rectal cancer who have received no prior treatment. participants who achieve complete clinical response (ccr) following dostarlimab treatment will undergo non-operative management (nom), including close surveillance for recurrent disease. the goal of the study is to determine if dostarlimab therapy alone is an effective treatment that can allow participants to avoid chemotherapy, radiation, and surgery.


Eligibility criteria:
inclusion criteria: * participant has histologically confirmed stage ii to iii (t3-t4, n0, or t any, n+), locally advanced rectal cancer * participant has radiologically and endoscopically evaluable disease. * participant has a tumor which can be categorized as dmmr or msi-h by local or central assessment exclusion criteria: * participant has distant metastatic disease. * participant has received prior radiation therapy, systemic therapy, or surgery for management of rectal cancer. * participant has any history of interstitial lung disease or pneumonitis * participant has experienced any of the following with prior immunotherapy: any irae of grade ≥3, immune-related severe neurologic events of any grade (e.g., myasthenic syndrome/myasthenia gravis, encephalitis, guillain barré syndrome, or transverse myelitis), exfoliative dermatitis of any grade (stevens-johnson syndrome, toxic epidermal necrolysis, or dress syndrome), or myocarditis of any grade. non clinically significant laboratory abnormalities are not exclusionary. * participant has a known additional malignancy that progressed or required active treatment within the past 2 years. exceptions include adequately treated superficial skin cancers, superficial bladder cancers, and other in situ cancers. * participant has an active autoimmune disease that has required systemic treatment in the past 2 years (i.e., with use of disease-modifying agents, corticosteroids, or immunosuppressive drugs). replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency) is not considered a form of systemic treatment. * participant has a history of severe allergic and/or anaphylactic reactions to chimeric, human or humanized antibodies, fusion proteins, or has known allergies to dostarlimab or its excipients. * has received or plans to receive an organ or stem cell transplant that uses donor stem cells (allogeneic stem cell transplant).

Keywords: jemperli dostarlimab-gxly gsk4057190a stage ii/iii rectal cancer neoadjuvant dmmr msi-h
xen matrix™ ab surgical graft in ventral or incisional midline hernias

Conditions: Incisional Hernia

Summary: this study aims to prospectively explore the use of xenmatrix™ ab surgical graft for ventral or incisional midline hernia repair in patients across all wound classes ("all comers") through 24 months post repair.

this is a post-market, on-label study to understand the performance of the graft in the us.

Eligibility criteria:
inclusion criteria: * subject must be willing and able to give written informed consent. * subject must be diagnosed with a ventral or incisional midline hernia. * mesh must be placed in the retro-rectus or intraperitoneal plane. * subject must be willing to undergo open hernia repair and be able to undergo all other study procedures as outlined in this protocol. exclusion criteria: * the use of surgical graft as a bridge repair. * the subject has more than 4 prior recurrences. * subject has a contraindication for the placement of surgical graft. * complete removal of existing mesh from a prior hernia repair (in the same affected area) is not possible. * the study hernia repair requires more than a single piece mesh (including sufficient overlap beyond margins of the defect on all sides). * subject has intact permanent mesh adjacent to the current hernia to be repaired. * subject has peritonitis at the time of surgery. * the subject is an active smoker within the last 2 weeks prior to surgery. * clinically significant chronic obstructive pulmonary disease or heart failure, defined as marked limitation in ability or inability to perform activities of daily living. * subject had chemotherapy within the last 12 months, is on or suspected to be placed on chemotherapy medications during any part of the study. * chronic steroid use (\>6 months) or immunosuppression drugs. * subject's body mass index (bmi) \>45 kg/m2. * subject has cirrhosis, and/or ascites. * subject has a defined collagen disorder. * known to be infected with human immunodeficiency virus (hiv). * subject has clinically significant (not based solely on creatinine levels) kidney disease that limits activities of daily living, is on hemodialysis or peritoneal dialysis. * subject is american society of anesthesiology (asa) class 4 or 5. * subject has a life expectancy \< 2 years at the time of enrollment. * subject is pregnant, breastfeeding or planning on becoming pregnant during the course of the study. * subjects with known sensitivity to porcine products. * subjects with allergy, history of allergy or hypersensitivity to tetracyclines (including minocycline) or rifamycins (including rifampin). * subject has any condition in the opinion of the investigator that would preclude the use of the study device, or preclude the subject from completing the follow-up requirements.
dynact imaging in evar: comparing clinical benefit of dynact to multidetector ct as the current gold standard.

Conditions: Abdominal Aortic Aneurysm

Summary: the aim of this study is to evaluate a new way to create ct-like images during intra-operative procedures. we want to prove that the quality and information received from dynact is satisfactory in implementing stent-graft in abdominal aortic aneurysm.

the study will compare images from the new modality (dynact) with the present modality (multi detectorct). we make three different set of images from each modality.

Eligibility criteria:
inclusion criteria: * age over 65, * satisfactory renal function
neuroregen scaffold™ with bone marrow mononuclear cells transplantation vs. intradural decompression and adhesiolysis in sci

Conditions: Spinal Cord Injury

Summary: the purpose of this study is to investigate the efficacy and safety of neuroregen scaffold with bone marrow mononuclear cells (bmmcs) on neurological recovery following chronic and complete spinal cord injury, compared to the treatment of surgical intradural decompression and adhesiolysis only.


Eligibility criteria:
inclusion criteria: 1. completely spinal cord injury at the thoracic level as assessed by magnetic resonance imaging (mri) and electrophysiology. 2. asia impairment scale (ais) grade a. 3. male or female, 18-60 years old. 4. no significant further improvement after injury and rehabilitation. 5. patients with normal peripheral nerve function and without muscle atrophy. 6. cardiovascular, respiratory, liver, kidney functions and laboratory examinations are within normal ranges. 7. no brain disease or mental disorder. 8. ability and willingness to regular visit to hospital and follow up during the protocol procedures. 9. patients signed informed consent. exclusion criteria: 1. a current diagnosis of any primary diseases affecting limb functions (e.g., traumatic brain injury, cerebral hemorrhage, cognitive disorders or other central nervous system diseases). 2. patients without any rehabilitation train after injury. 3. remarkable muscle atrophy or fibrosis. 4. degeneration of peripheral nerve function. 5. allergic constitution. 6. participation in any immunomodulator therapy or experimental drug treatment within 60 days prior to study. 7. suffering diabetes, autoimmune diseases, tumor or severe hypertension. 8. patients with severe heart, lung, liver or renal dysfunction are unable to meet the surgery standards. 9. severe bleeding tendency or abnormal coagulation function. 10. inflammation or skin ulcers at the surgical site. 11. lactating and pregnant woman. 12. poor compliance, difficult to complete the study. 13. any other conditions that might increase the risk of subjects or interfere with the clinical trial.
protective effect of probacine against negative gut metabolism and organ dysfunction after cardiovascular surgery (panda iv)

Conditions: Cardiovascular Disease; Cardiopulmonary Bypass

Summary: cardiovascular diseases (cvds) continue to be the primary cause of illness and death globally, emphasizing the pressing requirement for efficient prevention methods. recent studies indicate that the gut microbiome plays a vital role in maintaining cardiovascular health, affecting the pathophysiological mechanisms related to cvds. the potential therapeutic strategies for primary care practitioners included the modulation of the gut microbiome through dietary changes, prebiotics, and probiotics. the aim of this study was to investage the effect of gut microbiome modulation on clinical outcomes after cardiac surgery.


Eligibility criteria:
inclusion criteria: * adult men and women; * cardiovascular surgery; * agree to participate in the study and sign the informed consent form. exclusion criteria: * pregnant women; * patients with preexisting psychotic disorders; * decline to participate in the study.

Keywords: gut microbiota
survival and prognostic factors of primary retroperitoneal sarcomas after surgery: a single-center experience

Conditions: Primary Retroperitoneal Sarcoma

Summary: he percentage of retroperitoneal sarcomas (rps) among all soft tissue sarcomas ranges from 10%-15%. surgery remains the gold standard for rps. in this study, we analyzed the impact of surgical treatment for primary rps on recurrence and overall mortality at a chinese institution and identified and evaluated prognostic variables.


Eligibility criteria:
inclusion criteria: * the inclusion criteria were as follows: (1) diagnosis of primary retroperitoneal sarcoma, (2) pathological conformity, (3) no prior surgical resection, (4) complete clinicopathological data, and (5) age of ≥18. exclusion criteria: * patients with benign retroperitoneal tumors, gastrointestinal stromal tumors, ewing, desmoid-type fibromatosis, pheochromocytomas/paragangliomas, or any other subtypes other than rps were not included. the ethics committee of the northern jiangsu people's hospital approved the study.
myocilin variations and familial glaucoma in taxiarchis

Conditions: Glaucoma

Summary: taxiarchis, a small village in northern greece with 1060 inhabitants, was considered to have a surprisingly high incidence of glaucoma. this isolated population located on mount holomondas appeared to be enriched for familial glaucoma. based upon the high reported incidence of glaucoma in taxiarchis and previous findings of the thr377met myocilin mutation in the greek population,the investigators undertook a community-based study to determine if this variant was present in this village.


Eligibility criteria:
inclusion criteria: * individuals born in taxiarchis exclusion criteria: * individuals that have not been born in taxiarchis

Keywords: glaucoma myocilin
lux-head & neck 4: afatinib (bibw 2992) versus placebo for the treatment of head and neck squamous cell cancer after treatment with chemo-radiotherapy

Conditions: Head and Neck Neoplasms

Summary: this randomised, double-blind phase iii trial will be performed in patients with head and neck squamous cell carcinoma (hnscc). the objectives of the trial are to compare the efficacy and safety of afatinib (bibw 2992) with placebo as adjuvant therapy to patients who have received definitive chemo-radiotherapy.


Eligibility criteria:
inclusion criteria: * histologically or cytologically confirmed loco-regionally advanced head and neck squamous cell carcinoma (hnscc), stage iii to ivb * unresected tumour prior to chemo-radiotherapy (crt) * concomitant crt completed prior to randomisation * after concomitant platinum-based crt, no evidence of disease (ned) on clinical and radiographic examinations * eastern cooperative oncology group (ecog) performance status 0 or 1 exclusion criteria: * patients with smoking history of less than or equal to 10 pack years and with primary tumour site of base of tongue and/or tonsil * cancer of nasopharynx, sinuses, and/or salivary glands * prior treatment with epidermal growth factor receptor (egfr)-targeted small molecules, egfr-targeted antibodies, and/or any investigational agents for hnscc * known pre-existing interstitial lung disease (ild) * any past or present history of areca/betel-nut chewing or its derivatives for a cumulative duration of more than 3 months
responses of premature infants to measles-mumps-rubella (mmr) and varicella vaccines

Conditions: Measles; Mumps; Rubella; Varicella

Summary: the purpose of this study is to see if the mmr and chickenpox vaccines work as well in premature infants as in children that were carried to full term. a group of children who were carried full-term will be matched for age, sex, and race and will be used for comparison.

the purpose of this study is to see if the mmr and chickenpox vaccines work as well in premature infants as in children that were carried to full term. a group of children who were carried full-term will be matched for age, sex, and race and will be used for comparison. extremely premature infants (born at \ = 37 weeks gestation) at birth. infants will be vaccinated at visit 1 and post-vaccine serology will drawn at visit 2 (4 to 6 weeks after visit 1).

Eligibility criteria:
inclusion criteria: 1. premature infant \ = 37 weeks gestation at birth. 2. postnatal age \< 16 months, 0 days. 3. has not yet received mmr or varicella vaccines. (there are no restrictions on the administration of other vaccines at the time of mmr/varicella vaccination.) 4. parental permission. 5. agreement of primary care pediatrician/ health care provider. 6. receives primary pediatric care within an approximate 25-mile radius of the university of rochester. 7. healthy status at enrollment. exclusion criteria: 1. known immunodeficiency. 2. systemic corticosteroid therapy at the time of mmr/varicella vaccination. 3. requiring oxygen therapy. 4. clinically significant findings on review of medical history and physical exam determined by the investigator or sub-investigator to be sufficient for exclusion. 5. any condition determined by the investigator that would interfere with the evaluation of the vaccine or be a potential health risk to the subject.
does nmes help relieve lower limb oedema and improve joint mobility and skin tissue oxygenation levels?

Conditions: Oedema

Summary: neuromuscular electrical stimulation (nmes) will be facilitated through the use of a stimulator, with the patient in a semi recumbent position, using ultrastim electrodes. two 5 cm x 5 cm electrodes will be placed over the soleus muscle for calf stimulation. the participant will be allowed to ramp up the stimulus level themselves to get used to the sensation and determine their maximum tolerated stimulus level. a goniometer will be used to assess mobility at the knee and ankle joints. transcutaneous oxygen measurements (tcpo2) will be assessed using the perimed periflux system 500 tcpo2 monitor. the level of oedema will be measured using the figure of eight measurement, tape circumference measurement and water displacement measurement. comfort will also be assessed by use of a 100mm non-hatched visual analogue scale (vas). each participant will be asked to indicate their level of comfort following the application of nmes.

neuromuscular electrical stimulation (nmes) will be facilitated through the use of a two-channel, research stimulator, with the patient in a semi recumbent position, using ultrastim electrodes. two 5 cm x 5 cm electrodes will be placed over the soleus muscle for calf stimulation. the participant will be allowed to ramp up the stimulus level themselves to get used to the sensation and determine their maximum tolerated stimulus level. a goniometer will be used to assess mobility at the knee and ankle joints. transcutaneous oxygen measurements (tcpo2) will be assessed using the perimed periflux system 500 tcpo2 monitor. the level of oedema will be measured using the figure of eight measurement, tape circumference measurement and water displacement measurement. comfort will also be assessed by use of a 100mm non-hatched visual analogue scale (vas). each participant will be asked to indicate their level of comfort following the application of nmes. vas pain scores of 30 mm or less will be categorised as mild pain, between 31 and 69 mm as moderate pain, and scores of 70 mm or greater as severe pain.

Eligibility criteria:
inclusion criteria: * patients that present to merlin park podiatry clinic for podiatric intervention who on clinical examination present with lower lib swelling/oedema/ * ability to understand the nature of the study. * ability to give informed consent. exclusion criteria: * skin ulceration in area of intended electrical stimulation site. * psychiatric disorder. * severe co-morbidity. * patients with uncontrolled heart problems. * patients with pacemakers, dbs. * patients on opioid or neuropathic pain medication.

Keywords: joint mobility skin tissue oxygenation neuromuscular electrical stimulation goniometry transcutaneous oxygen measurements (tcpo2) water displacement
predictors of mortality in patients with autoimmune diseases admitted to the intensive care unit

Conditions: Vasculitis; Systemic Lupus Erythematosus; Myositis

Summary: autoimmune diseases, such as systemic lupus erythematosus, rheumatoid arthritis, myositis, or anti-neutrophil cytoplasmic antibody (anca)-associated vasculitis, may affect multiple organ systems. occasionally, patients deteriorate acutely requiring advanced care in an intensive care unit (icu). in an icu setting, mortality is estimated with scoring systems, such as apache or sapsii. since there are limited data available on their use in autoimmune diseases, with the current study, we aim to assess the usefulness of these icu scores and analyze predictors of mortality in this particular group of patients.


Eligibility criteria:
inclusion criteria: * patients admitted to the icu at the university medical center göttingen exclusion criteria: * patients with incomplete or missing data

Keywords: intensive care unit mortality autoimmune diseases
aims medical outcomes study

Conditions: Mental Health Issue; PTSD; Pain; Chronic Pain; Chronic Disease

Summary: this epidemiologic research is being conducted as an observational prospective case series outcomes study of the use of advanced integrative specialty medical care and its effect on adult and pediatric patients with chronic or serious illnesses or mental health disorders.

there is growing interest in providing integrative medical care in conjunction with specialty medical care to expand the reach of integrative care to more chronically and seriously ill patient populations. at the aims institute, the core specialties are naturopathy, palliative care, psychiatry, physiatry, and naturopathic oncology practiced via coordinated, team-based care by allopathic medical and psychiatric specialists, psychotherapists, specialized naturopathic physicians, advanced practice nurses, and targeted health educators, with the majority of care covered by insurance. additionally incorporated are novel 'advanced' approaches, such as drug-assisted psychotherapy, medical cannabis education, sympathetic blocks, and some intravenous therapies. this is an uncontrolled, prospective case series outcomes study of health-related quality of life outcomes in patients who receive care at aims institute. a clinic-wide chart audit of patient characteristics and outcomes will be conducted prior to the start of enrollment.

Eligibility criteria:
inclusion criteria: * patients enrolled in the study will meet the following criteria: 1. a new patient coming in for a first office call (foc) or first consultation via telemedicine with an aims physician or advanced practice provider; 2. an established patient; 3. if over 18 years of age are able to understand study design adequately and provide signed informed consent to enrollment; 4. if younger than 18 years of age informed consent from a parent or guardian who is able to understand the study design adequately and provide signed informed consent for the pediatric patient. exclusion criteria: * ineligible participants: 1. cannot read or understand english well enough to read and sign the consent form and complete the questionnaires; 2. unwilling to participate in the aims institute observational study.

Keywords: naturopathic oncology integrative medicine integrative psychiatry integrative physical medicine and rehabilitation integrative palliative care medicine serious illness life threatening illness